Scott Terrillion - Cara Therapeutics Executive
| 69C Stock | EUR 4.84 0.00 0.00% |
Executive
Mr. Scott M. Terrillion serves as General Counsel, Secretary and Chief Compliance Officer of the company. Mr. Terrillion brings over 20 years of diverse pharmaceutical industry experience from varying legal and business roles in the public, private and notforprofit sectors. Mr. Terrillion spent 15 years at Boehringer Ingelheim Pharmaceuticals, Inc., a researchdriven pharmaceutical company, where he served as Vice President, Associate General Counsel. At Boehringer, Mr. Terrillion built and led the legal team supporting the global companys U.S. human pharmaceutical business during a period of rapid, industryleading growth. Mr. Terrillion also spent two years at Mesoblast, Inc., a publicly traded emerging biotech, as the companys Vice President, Associate General Counsel and Head of Compliance. Mr. Terrillion began his legal career at Nixon, Hargrave, Devans Doyle, a large general practice law firm, where he was an associate in the Health Care and TechnologyIntellectual Property Practice groups. A licensed pharmacist, Mr. Terrillion began his professional career as a community pharmacist and later served as Director of Pharmacy for Preferred Care, Inc., an HMO insurance provider since 2016.
| Age | 60 |
| Tenure | 9 years |
| Phone | 203 406 3700 |
| Web | https://www.caratherapeutics.com |
Scott Terrillion Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Terrillion against Cara Therapeutics stock is an integral part of due diligence when investing in Cara Therapeutics. Scott Terrillion insider activity provides valuable insight into whether Cara Therapeutics is net buyers or sellers over its current business cycle. Note, Cara Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cara Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Terrillion over two weeks ago Disposition of 163 shares by Scott Terrillion of Cara Therapeutic at 4.76 subject to Rule 16b-3 | ||
Scott Terrillion over a month ago Disposition of 1642 shares by Scott Terrillion of Cara Therapeutic at 11.91 subject to Rule 16b-3 | ||
Scott Terrillion over three months ago Disposition of 2483 shares by Scott Terrillion of Cara Therapeutic at 3.51 subject to Rule 16b-3 | ||
Scott Terrillion over six months ago Acquisition by Scott Terrillion of 13500 shares of Cara Therapeutic subject to Rule 16b-3 |
Cara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2558) % which means that it has lost $0.2558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4516) %, meaning that it generated substantial loss on money invested by shareholders. Cara Therapeutics' management efficiency ratios could be used to measure how well Cara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Cara Therapeutics has accumulated 4.99 M in total debt with debt to equity ratio (D/E) of 4.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Cara Therapeutics has a current ratio of 3.33, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cara Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Cara Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cara Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cara to invest in growth at high rates of return. When we think about Cara Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 8 records | EXECUTIVE Age | ||
| Dawn Linaker | Collins Foods Limited | N/A | |
| Frances Finucan | Collins Foods Limited | N/A | |
| Lee Woo | Agricultural Bank of | N/A | |
| Guoqiang Han | Agricultural Bank of | 56 | |
| Drew OMalley | Collins Foods Limited | N/A | |
| Mingde Yao | Agricultural Bank of | N/A | |
| Han Xu | Agricultural Bank of | 58 | |
| Zhi Li | Agricultural Bank of | 60 | |
Management Performance
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 |
Cara Therapeutics Leadership Team
Elected by the shareholders, the Cara Therapeutics' board of directors comprises two types of representatives: Cara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cara. The board's role is to monitor Cara Therapeutics' management team and ensure that shareholders' interests are well served. Cara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joana Goncalves, Chief Medical Officer | ||
| Christopher Posner, Director | ||
| Beth Weinberg, VP QA | ||
| Eric Vandal, VP Commercial | ||
| Frdrique Menzaghi, Chief RD | ||
| Iris Francesconi, Chief Relations | ||
| Scott Terrillion, Chief Compliance Officer, General Counsel, Secretary | ||
| Dr DSc, CoFounder Advisor | ||
| Ryan Maynard, Chief Officer |
Cara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.25) % | |||
| Operating Margin | (2.28) % | |||
| Current Valuation | 450.58 M | |||
| Shares Outstanding | 53.73 M | |||
| Shares Owned By Insiders | 16.10 % | |||
| Shares Owned By Institutions | 65.69 % | |||
| Price To Book | 3.33 X | |||
| Price To Sales | 14.36 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Cara Stock
Cara Therapeutics financial ratios help investors to determine whether Cara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cara with respect to the benefits of owning Cara Therapeutics security.